GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 261,900 shares, a decrease of 58.0% from the August 15th total of 623,300 shares. Based on an average daily volume of 7,030,000 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC bought a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned about 91.38% of GeoVax Labs as of its most recent SEC filing. 6.09% of the stock is currently owned by institutional investors and hedge funds.

GeoVax Labs Stock Down 9.3 %

Shares of NASDAQ:GOVX traded down $0.29 during mid-day trading on Friday, hitting $2.84. The stock had a trading volume of 1,412,505 shares, compared to its average volume of 2,647,191. The company’s 50 day moving average is $3.57 and its 200-day moving average is $2.49. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($1.99) EPS for the quarter, beating the consensus estimate of ($2.57) by $0.58. The company had revenue of $0.30 million for the quarter. During the same quarter in the prior year, the company posted ($3.30) EPS. As a group, research analysts expect that GeoVax Labs will post -5.1 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on GOVX shares. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research report on Monday, August 12th. Roth Mkm started coverage on shares of GeoVax Labs in a report on Tuesday, July 16th. They set a “buy” rating and a $20.00 price objective for the company. Roth Capital upgraded shares of GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 16th. Noble Financial lifted their price target on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research note on Monday, August 19th. Finally, EF Hutton Acquisition Co. I upgraded GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, GeoVax Labs currently has a consensus rating of “Buy” and an average target price of $12.67.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.